Articles
Turning from the provision of care to the provision of therapies and essential personal protective equipment (PPE), Mr Pourmahram and Dr Fortner focused on the wholesale supply chain and the challenges of ensuring an uninterrupted flow of crucial materials to areas with the greatest demand. Read More ›
Less than a month after California issued a stay-at-home order in response to the COVID-19 crisis, oncology practices are seeing declines in their revenue cycles. Mr Gockerman and Mr Shah analyzed the strategies needed to mitigate the downturn. Read More ›
Dr Peskin, Dr Breidbart, and Mr Eyles gave an overview of the changes the novel coronavirus has prompted for managed care payers. They agreed that the unprecedented set of circumstances surrounding the pandemic has led to an opening of the floodgates to questions without immediate answers, leaving providers and payers in unfamiliar territory in a rapidly changing environment with few guideposts. Read More ›
The Centers for Medicare & Medicaid Services (CMS) has broadened access to Medicare telehealth services so that beneficiaries can receive a wider range of services from their physicians without having to travel to a healthcare facility. Clinicians can bill immediately for services starting March 6, 2020. Read More ›
The March issue of The Oncology Pharmacist (TOP) features the latest medical news, expert perspectives, clinical trial results, and drug updates, as well as important highlights from national and international meetings, including the 2019 ASH annual meeting, the 2019 Supportive Care in Oncology Symposium, the NCCN 2019 Hematologic Malignancies meeting, the ACCC 2019 National Oncology Conference, and the 2019 AVBCC Summit. Read More ›
By Phoebe Starr
Orlando, FL—Chimeric antigen receptor (CAR) T-cell therapy is now approved as third-line treatment for patients with B-cell lymphomas and leukemias. For some patients, CAR T-cell therapy is a miracle therapy, extending survival and, in some cases, as a bridge to a potentially curative transplant. Read More ›
By Wayne Kuznar
Orlando, FL—Nivolumab monotherapy can be used as an effective bridge therapy to autologous hematopoietic cell transplantation (AHCT) in many patients with relapsed or refractory Hodgkin lymphoma (HL), researchers reported at the 2019 American Society of Hematology (ASH) annual meeting. Read More ›
New York City, NY—By its very nature, oncology is rife with change, with new research resulting in treatment advances at a rapid pace. Pending federal legislation aimed at reining in prescription drug prices and an upcoming presidential election may introduce yet further changes in oncology. Read More ›
By Corbin Davis
San Francisco, CA—According to results from a retrospective analysis of nearly 12,000 patients with cancer, increased social support may function as an analgesic and help to mitigate pain. Read More ›
By Chase Doyle
Orlando, FL—The impact of poverty and low socioeconomic status on health and survival among children may be even more debilitating than suspected, according to new data presented at ASH 2019. Read More ›